Paul Dent, PhD

Universal Chair in Signal Transduction

Signal Transduction

  • B.Sc. (1st) 1988, Biochemistry, University of Newcastle upon Tyne, England
  • Ph.D. 1992, (with Professor Sir P. Cohen, F.R.S.) Biochemistry, University of Dundee, Scotland
  • Postdoctoral Fellow (with Professor T. W.Sturgill), University of Virginia, Charlottesville, Virginia


The laboratory of Dr. Paul Dent is dedicated to developmental cancer therapeutics. NIH and Department of Defense funded projects have focused on the rational combination of drugs and other molecules to kill tumor cells in vitro and in vivo. Studies have focused on the underlying molecular mechanisms by which our drug combinations synergize to kill tumor cells including modulation of apoptosis, autophagy, colony formation and changes in multiple cell signaling pathways. Specific projects have focused on breast; brain; and liver/pancreatic cancers. Our studies in breast cancer have resulted in a Phase I trial combining pemetrexed and sorafenib which will shortly move into Phase II evaluation. Our studies in brain cancer have resulted in two Phase I trials with a third trial using the novel cytokine MDA-7/IL-24 in the late stages of planning. Our studies in liver and pancreatic cancers have resulted in one trial combining sorafenib and HDAC inhibitors, with another trial in the late stages of planning. Other studies in solid tumors and in colon cancer are approaching clinical translation.

View Dr. Dent's Publications via the National Library of Medicine's PubMed.

Paul Dent, PhD
Professor and Universal Chair in Signal Transduction
Dept. of Biochemistry & Molecular Biology
Virginia Commonwealth University
VCU Massey Cancer Center
401 College Street

Richmond, VA 23298-0035

  •      804-628-0861